Methods: Our standardization process included multiple steps. A preliminary study collected force—time profiles from 9 experienced clinicians delivering HVLA-SM to 16 asymptomatic participants. Mean thrust loading durations, pre-load forces and peak thrust forces in the lumbar spine were: 308 ± 389 ms; 116 ± 69 N; and 261 ± 143 N, respectively. We trained 3 clinicians to deliver HVLA-SM to within 1 SD of the calculated means and conducted a pilot study of patients with LBP. Force—time profiles were collected at 1—3 visits on 4 participants receiving HVLA-SM and all but 1 manipulation was within the standardized force ranges. We then conducted a focus group with the 9 clinicians from our preliminary study to determine what doctor and patient characteristics they considered important when evaluating the quality of SM. This led to the inclusion of surveys in the RCT of 219 participants asking both the clinician and patient to rate their perceptions of SM quality. We video recorded HVLA-SM treatment on specified visits that were evaluated by an independent clinician.

Results: The preliminary study consisted of 16 asymptomatic participants (15 males, mean BMI 26, mean age 36). Further analysis revealed a total of 28 segments were manipulated with much variability found both amongst the clinicians and the segmental levels. Between clinicians, the thrust loading duration varied by 0 — 1940 ms, preload range was 41 — 216 N and peak force range was 67 — 462 N. Preload per segment range was 64 N at L5 to 154 N at L4 and peak force range from 134 N at the sacrum to 402 N at L4. Eight clinicians delivered thrust forces with the hand and one with the leg. Pilot study clinicians stated that maintaining the specified force—time profile was difficult and limited their care. The focus group felt that the force—time profile was only one of several necessary components in high quality HVLA-SM. Analysis of 133 visits during the RCT showed that clinician and patient perceived quality of HVLA-SM delivery for the same treatment was different. Patients rated quality average 5%, very good 37% and excellent 55% of the time. Clinicians rated their own quality average 30%, very good 67% and excellent 2% of the time. Evaluation of 54 video recorded encounters focused on potential quality parameters identified by the study team showed significant variation between and within clinicians.

Conclusion: Clinicians used their judgment in applying force—time profiles and we collected qualitative data to objectively assess HVLA-SM quality. It is premature to standardize HVLA-SM based upon force—time profiles of thrusting hand alone, due to different delivery styles. More research is needed to effectively standardize HVLA-SM delivery.

doi: 10.1016/j.clch.2011.09.014

Effects of Biofreeze vs. ice on acute, non-complicated neck pain

Bart Bishop*, Jay Greenstein, Robert Topp

*Corresponding author.
E-mail address: drjay@ssrehab.com

Abstracts from the WFC’s 11th Biennial Congress 153
average pre-treatment VAS score went from 6.24 to 3.65 for Biofreeze and from 6.31 to 5.00 for ice. A paired t-test demonstrated that both ice and Biofreeze gave a significant reduction on pain levels (p < 0.001); however, there was nearly 2 times the reduction of pain on the Biofreeze side.

**Conclusions:** Both ice and Biofreeze significantly decreased pain levels; however, Biofreeze decreased pain nearly 2 times as much as ice. In addition, it was rated as substantially more comfortable, patients preferred it, and it lasted longer 9 out of 10 times. This is the first study to evaluate solely the immediate effects of two different cryotherapy methods and, as such, it is not unexpected that the results of this study would differ slightly from other published studies evaluating menthol products. Conservative care specialists are often looking for methods to improve patient satisfaction and compliance and with the results significantly favoring Biofreeze this is recommended as the primary method of cryotherapy application on the first visit.


---

Dose—response of spinal manipulation for low back pain: Short-term outcomes from a randomized trial

Mitchell Haas*, Darcy Vavrek, David Peterson, Mikel Aickin

*Corresponding author.
E-mail address: mhaas@uws.edu

**Introduction:** There is increasing evidence that suggests the efficacy of spinal manipulation for the treatment of chronic low back pain (LBP). Yet, there have been no large trials to determine optimal number of treatments with manipulation. Our pilot study suggested greater pain and disability improvement for higher doses of manipulation. The current study is the first full-scale randomized trial to evaluate optimal dose and efficacy of manipulation, while controlling attention bias, patient touch, and expectation associated with quantity of care.

**Methods:** 400 participants with chronic LBP were randomized to 4 doses (n = 100/group), using design adaptive allocation to balance baseline variables across groups. Participants were seen by one of 10 study chiropractors 18 times (3 times per week for 6 weeks). Patients received 0, 6, 12, or 18 sessions of spinal manipulation, and a light massage control on visits without manipulation. All patients received a hot pack and low intensity pulsed ultrasound at each visit.

The primary outcomes were the 100-point Modified Von Korff Pain and Disability Scales at 12 and 24 weeks. Secondary outcomes included days with pain and disability in the last four weeks, fear avoidance and SF12 physical and mental health component summaries. An intention-to-treat analysis was conducted using ANCOVA to identify linear dose effects (slope) adjusted for baseline differences between groups. Significance level was set for tests of four primary outcomes (I^2/4*0.0125). More sophisticated dose—response curve analysis will also be presented.

**Results:** The mean baseline pain was 67.3 (SD = 18.6), disability was 45 (SD = 22.8), days with LBP were 24.1 (SD = 5.1), and days with LBP-related disability were 6.8 (SD = 7.5). The overall mean pain and disability improvement for the sample was approximately 50% at 12 weeks and was sustained to 24 weeks. For the primary outcomes, the linear effects at 12 weeks were statistically significant and of modest magnitude favoring higher dose: pain slope = 2.7 points/group (95% CI = 1.0—4.5, P = .002) and disability slope = 2.3 points/group (95% CI = 0.6—4.0, P = .009). The linear effects were diminished at 24 weeks: pain slope = 1.2 points/group (95% CI = −0.5 to 3.0, P = .176) and disability slope = 1.4 points/group (95% CI = −0.3 to 3.2 to 4.5, P = .114). For the secondary outcomes, there were modest statistically significant linear effects for days with pain and disability at 12 weeks; the effect was sustainable to 24 weeks for days with pain. The SF12 physical component summary was statistically significant at 12 weeks. Meaningful linear effects were not found for other variables.

**Conclusions:** Modest linear dose—response effects favoring higher dose were found for pain and disability at 12 weeks. The linear effects were halved at 24 weeks.